Stéphane Bernhard

This paper develops a hydrogel that enables subcutaneous delivery of vesicant antibody-drug conjugates by confining them in a depot, reducing tissue damage while maintaining antitumor efficacy.

This paper develops a hydrogel platform for subcutaneous delivery of trastuzumab, achieving sustained release over 3 days in vitro and in vivo.

This paper develops photosynthetic living materials that sequester CO2 through dual mechanisms, achieving 2.5 mg CO2 per gram of material over 30 days.